Table of contents
Expand All Topics
Membranoproliferative glomerulonephritis
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of membranoproliferative glomerulonephritis are prepared by our editorial team based on guidelines from the Kidney Disease: Improving Global Outcomes Foundation (KDIGO 2021).
1
Diagnostic investigations
Evaluation for etiology, IC-MPGN: as per KDIGO 2021 guidelines, evaluate patients with immune complex-mediated glomerulonephritis for underlying disease:
Situation
Guidance
Infections
HCV and HBV infections, endocarditis, infected ventriculoatrial shunt, visceral abscess, leprosy, meningococcal meningitis
Autoimmune diseases
SLE, Sjögren's disease, rheumatoid arthritis, mixed connective tissue disease
Monoclonal gammopathy
Plasma cell or B-cell disorder
Other
Fibrillar glomerulonephritis, idiopathic
E
Show 2 more
More topics in this section
Evaluation for etiology (C3G)
Medical management
Management of immune complex-mediated MPGN: as per KDIGO 2021 guidelines, focus on the treatment of the underlying pathologic process as the initial approach to management when the cause of immune complex-mediated glomerulonephritis is determined.
E
Show 7 more
More topics in this section
Management of C3 glomerulopathy